Victor M Lu

Dr. Victor M Lu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2020 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
VLVictor M Lu
Victor M Lu
KOKyle P. O’cOnnor
Kyle P. O’cOnnor
ASAshish H. Shah
Ashish H. Shah
DEDaniel G. Eichberg
Daniel G. Eichberg
ELEvan M. Luther
Evan M. Luther
Michael E. IvanMichael E. Ivan
Michael E. Ivan

1 July 2018 in World Neurosurgery
Verified
Journal Article
Closed access
VLVictor M Lu
Victor M Lu
TJToni R. Jue
Toni R. Jue
KMKerrie L. McDonald
Kerrie L. McDonald
RRRichard A. Rovin
Richard A. Rovin

28 June 2019 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
VLVictor M Lu
Victor M Lu
KRKrishnan Ravindran
Krishnan Ravindran
CGChristopher S. Graffeo
Christopher S. Graffeo
APAvital Perry
Avital Perry
JGJamie J. Van Gompel
Jamie J. Van Gompel
MLMichael J. Link
Michael J. Link

1 March 2019 in Journal of neurosurgery. Pediatrics
Verified
Journal Article
Closed access
PDF file
VLVictor M Lu
Victor M Lu
MAMohammed Ali Alvi
Mohammed Ali Alvi
KMKerrie L. McDonald
Kerrie L. McDonald
DDDavid J. Daniels
David J. Daniels
OBJECTIVE: Pediatric high-grade gliomas (pHGGs), including diffuse intrinsic pontine glioma, present a prognostic challenge given their lethality and rarity. A substitution mutation of lysine for methionine at position 27 in histone H3 (H3K27M) has been shown to be highly specific to these tumors. Data are accumulating regarding the poor outcomes of patients with these tumors; however, the quantification of pooled outcomes has yet to be done, which could assist in prioritizing management. The aim of this study was to quantitatively pool data in the current literature on the H3K27M mutation as an independent prognostic factor in pHGG.METHODS: Searches of seven electronic databases from their inception to March 2018 were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data were extracted and pooled using a meta-analysis of proportions. Meta-regression was used to identify potential sources of heterogeneity.RESULTS: Six observational studies satisfied the selection criteria for inclusion. They reported the survival outcomes of a pooled cohort of 474 pHGG patients, with 258 (54%) and 216 (46%) patients positive and negative, respectively, for the H3K27M mutation. Overall, the presence of the mutation was independently and significantly associated with a worse prognosis (HR 3.630, p < 0.001). Overall survival was significantly shorter (by 2.300 years; p = 0.008) when the H3K27M mutation was present in pHGG. Meta-regression did not identify any study covariates of heterogeneous concern.CONCLUSIONS: According to the current literature, pHGG patients positive for the H3K27M mutation are more than 3 times more susceptible to succumbing to this disease by more than 2 years, compared to patients negative for the mutation. More robust outcome data are required to improve our quantitative understanding of this pathological entity in order to assist in prioritizing clinical management. Future larger prospective studies are required to overcome inherent biases in the current literature to validate the quantitative findings of this study.

1 July 2019 in World Neurosurgery
Verified
Journal Article
Closed access
VLVictor M Lu
Victor M Lu
AGAnshit Goyal
Anshit Goyal
CGChristopher S Graffeo
Christopher S Graffeo
APAvital Perry
Avital Perry
TBTerry C. Burns
Terry C. Burns
KCKaisorn L. Chaichana
Kaisorn L. Chaichana

6 September 2019 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
JRJulian S. Rechberger
Julian S. Rechberger
VLVictor M Lu
Victor M Lu
LZLiang Zhang
Liang Zhang
EPErica A. Power
Erica A. Power
DDDavid J Daniels
David J Daniels